Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

19 Feb 2024

Abstract excerpt

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine booster (XBB.1.5 MV) to previously uninfected individuals...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38377995
DOI: 10.1016/j.chom.2024.01.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1PMID 38377995Read ↗

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against emerging SARS-CoV-2 variantsSemantic proximity Read ↗

Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine BoosterSemantic proximity Read ↗

The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteinsSemantic proximity Read ↗

Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variantsSemantic proximity Read ↗

Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineagesSemantic proximity Read ↗

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read ↗

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 VaccineSemantic proximity Read ↗

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent boosterSemantic proximity Read ↗

Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 VaccineSemantic proximity Read ↗

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1Semantic proximity Read ↗

Heterologous inactivated virus/mRNA vaccination response to BF.7, BQ.1.1, and XBB.1Semantic proximity Read ↗

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.